Oral fludarabine and cyclophosphamide in previously untreated chronic lymphocytic leukemia (CLL): Preliminary data.

被引：0
|
作者：
Cazin, B
Binet, JL
Divine, M
Lepretre, S
Lederlin, P
Travade, P
Lemaire, G
Guibon, O
机构：
[1] CHU Lille, F-59037 Lille, France
[2] CHU, Paris, France
[3] CHU, Creteil, France
[4] CHU, Rouen, France
[5] CHU, Nancy, France
[6] CHU, Clermont Ferrand, France
[7] Schering SA, Dardilly, France
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2218
引用
收藏
页码：515A / 515A
页数：1
相关论文
共 50 条
  • [21] Preliminary results of the combination rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) followed by rituximab maintenance in previously untreated chronic lymphocytic leukemia
    Bosch, Francesc
    Muntanola, Ana
    Villamor, Neus
    Terol, Maria Jose
    Gonzalez-Barca, Elena
    Ribera, Josep Maria
    Gonzalez, Marcos
    Abella, Eugenia
    Delgado, Julio
    Carbonell, Felix
    Garcia-Marco, Jose A.
    Escoda, Lourdes
    Ferrer, Secundino
    Monzo, E.
    Gonzalez, Yolanda
    Abrisqueta, Pau
    Salamero, Olga
    Gine, Eva
    Montserrat, Emili
    BLOOD, 2007, 110 (11) : 193A - 193A
  • [22] Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study
    Bosch, Francesc
    Cantin, Guy
    Cortelezzi, Agostino
    Knauf, Wolfgang
    Tiab, Mourad
    Turgut, Mehmet
    Zaritskey, Andrey
    Merot, Jean-Louis
    Tausch, Eugen
    Trunzer, Kerstin
    Robson, Susan
    Gresko, Ekaterina
    Boettcher, Sebastian
    Foa, Robin
    Stilgenbauer, Stephan
    Leblond, Veronique
    LEUKEMIA, 2020, 34 (02) : 441 - 450
  • [23] Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study
    Francesc Bosch
    Guy Cantin
    Agostino Cortelezzi
    Wolfgang Knauf
    Mourad Tiab
    Mehmet Turgut
    Andrey Zaritskey
    Jean-Louis Merot
    Eugen Tausch
    Kerstin Trunzer
    Susan Robson
    Ekaterina Gresko
    Sebastian Böttcher
    Robin Foà
    Stephan Stilgenbauer
    Véronique Leblond
    Leukemia, 2020, 34 : 441 - 450
  • [24] Long-Term Survival After Fludarabine, Cyclophosphamide, and Rituximab Treatment in Previously Untreated Chronic Lymphocytic Leukemia Patients
    Mustafa, Shokhan Mohammad
    Yassin, Ahmed Khudair
    Hassan, Kawa M.
    Sadiq, Nawsherwan
    Nadihm, Marwa N.
    Abdulrahman, Lara Lateef
    Salahaden, Shlan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S263 - S264
  • [25] A Multicenter Phase II Study Evaluating Fludarabine, Cyclophosphamide, and Subcutaneous Campath (FCCAM) for Previously Untreated Chronic Lymphocytic Leukemia
    Coutre, Steven E.
    Nabhan, Chadi
    BLOOD, 2014, 124 (21)
  • [26] Long-Term Survival After Fludarabine, Cyclophosphamide, and Rituximab Treatment in Previously Untreated Chronic Lymphocytic Leukemia Patients
    Mustafa, Shokhan Mohammad
    Yassin, Ahmed Khudair
    Mohammed, Nawsherwan S.
    Shamoon, Rawand P.
    Karma, Marwa N.
    Mohammad, Shlan S.
    Abdulrahman, Lara Lateef
    Ahmed, Zhalla O.
    Rashid, Bryar Sabah
    Mahmood, Tavan I.
    Yousif, Rozhhat A.
    Hasan, Kawa M.
    Mohamed, Zaki A.
    Getta, Hisham A.
    Jalal, Sana D.
    Abdullah, Dana A.
    Abdulla, Basil K.
    Numan, Ghanim S.
    Karadagh, Ranan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S260 - S261
  • [27] Long-term survival after fludarabine, cyclophosphamide, and rituximab treatment in previously untreated chronic lymphocytic leukemia patients
    Mustafa, Shokhan Mohammad
    Yassin, Ahmed Khudair
    Mohammed, Nawsherwan S.
    Shamoon, Rawand P.
    Karam, Marwa N.
    Mohammad, Shlan S.
    Abdulrahman, Lara Lateef
    Ahmed, Zhalla O.
    Rashid, Bryar Sabah
    Mahmood, Tavan, I
    Yousif, Rozhhat A.
    Hasan, Kawa M.
    Mohamed, Zeki A.
    Getta, Hisham A.
    Jalal, Sana D.
    Abdullah, Dana A.
    Abdulla, Basil K.
    Numan, Ghanim S.
    Karadagh, Ranan
    IRAQI JOURNAL OF HEMATOLOGY, 2021, 10 (02) : 139 - 145
  • [28] Chemoimmunotherapy With Low-Dose Fludarabine and Cyclophosphamide and High Dose Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia
    Foon, Kenneth A.
    Boyiadzis, Michael
    Land, Stephanie R.
    Marks, Stanley
    Raptis, Anastasios
    Pietragallo, Louis
    Meisner, Dennis
    Laman, Andrew
    Sulecki, Mathew
    Butchko, Allyson
    Schaefer, Patricia
    Lenzer, Diana
    Tarhini, Ahmad
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (04) : 498 - 503
  • [29] High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia
    Cazin, Bruno
    Divine, Marine
    Lepretre, Stephane
    Travade, Philippe
    Tournilhac, Olivier
    Delmer, Alain
    Jaubert, Jerome
    Feugier, Pierre
    Dreyfus, Brigitte
    Mahe, Beatrice
    Grosbois, Bernard
    Maloisel, Frederic
    Eghbali, Houchingue
    Dumontet, Charles
    Benichou, Jacques
    Guibon, Odile
    Leleu, Xavier
    Leporrier, Michel
    Maloum, Karim
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 143 (01) : 54 - 59
  • [30] Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia
    Boogaerts, MA
    Van Hoof, A
    Catovsky, D
    Kovacs, M
    Montillo, M
    Zinzani, PL
    Binet, JL
    Feremans, W
    Marcus, R
    Bosch, F
    Verhoef, G
    Klein, M
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (22) : 4252 - 4258
12345